 ARC-HIF0 is an RNAi-based therapeutic designed to reduce the production of hypoxia-inducible factor 0α (HIF-0α) to treat clear cell renal cell carcinoma. It is the first drug candidate using a new DPC™ delivery vehicle designed to target tissues outside of the liver. Arrowhead is conducting 